<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2018-1-47-54</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-830</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Comparative chemoreactome analysis of dexketoprofen, ketoprofen, and diclofenac</article-title><trans-title-group xml:lang="ru"><trans-title>Сравнительный хемореактомный анализ декскетопрофена, кетопрофена и диклофенака</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Торшин</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Torshin</surname><given-names>I. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаборатория фармакоинформатики,</p><p>119333, Москва, ул. Вавилова, 40</p></bio><bio xml:lang="en"><p>Laboratory of Pharmacoinformatics, </p><p>40, Vavilov St., Moscow 119333</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Громова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Gromova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаборатория фармакоинформатики,</p><p>119333, Москва, ул. Вавилова, 40</p></bio><bio xml:lang="en"><p>Laboratory of Pharmacoinformatics, </p><p>40, Vavilov St., Moscow 119333</p></bio><email xlink:type="simple">unesco.gromova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Федотова</surname><given-names>Л. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Fedotova</surname><given-names>L E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>153000, Иваново, Шереметевский пр., 8</p></bio><bio xml:lang="en"><p>8, Sheremetevsky Pr., Ivanovo 153000</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Громов</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Gromov</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаборатория фармакоинформатики,</p><p>119333, Москва, ул. Вавилова, 40</p></bio><bio xml:lang="en"><p>Laboratory of Pharmacoinformatics, </p><p>40, Vavilov St., Moscow 119333</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральный исследовательский центр «Информатика и управление» РАН</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Center «Informatics and Control», Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Ивановская государственная медицинская академия» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ivanovo State Medical Academy, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>02</day><month>04</month><year>2018</year></pub-date><volume>10</volume><issue>1</issue><fpage>47</fpage><lpage>54</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Torshin I.Y., Gromova O.A., Fedotova L.E., Gromov A.N., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Торшин И.Ю., Громова О.А., Федотова Л.Э., Громов А.Н.</copyright-holder><copyright-holder xml:lang="en">Torshin I.Y., Gromova O.A., Fedotova L.E., Gromov A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/830">https://nnp.ima-press.net/nnp/article/view/830</self-uri><abstract><p>Cyclooxygenase-2 (COX-2) is the main targeted protein of non-steroidal anti-inflammatory drugs (NSAID); nevertheless, the latter substantially differ in pharmacological properties.</p><sec><title>Objective</title><p>Objective: to establish the spectrum of pharmacological actions of dexketoprofen, ketoprofen, and diclofenac, by using a chemoreactome analysis.</p></sec><sec><title>Material and methods</title><p>Material and methods. A chemoinformation analysis was used to determine a list of the chemical structures closest to dexketoprofen. For each molecule, the investigators extracted the results of experimental measurements of the rheological properties of this molecule from databases and a chemoreactome analysis was carried out. The comparative chemoreactome analysis of the molecule of dexketoprofen and control molecules (ketoprofen, diclofenac) could assess the biological activity of the studied molecule.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Unlike the molecules of comparison, dexketoprofen was found to be able to accumulate mainly in muscles, adipose tissue, and adrenal glands. The anti-inflammatory and analgesic effect of dexketoprofen can be carried out via modulation not only of the metabolism of prostaglandins, but also that of leukotrienes and encephalins, as well as via inhibition of metalloproteinases and glutamate receptors. In addition, the analysis showed a considerable difference in the interaction profiles of dexketoprofen, ketoprofen, and diclofenac with cytochrome P450 enzymes. Dexketoprofen can enhance the efficacy of anti-arrhythmic and antiadrenergic agents, whereas ketoprofen and diclofenac are able to negatively affect the metabolism of omega-3 polyunsaturated fatty acids and vitamin D.</p></sec><sec><title>Conclusion</title><p>Conclusion. The chemoreactome analysis could identify the promising vasodilatory, antiplatelet, antidiabetic, and antitumor effects of dexketoprofen in addition to its main action. </p></sec></abstract><trans-abstract xml:lang="ru"><p>Основным таргетным белком нестероидных противовоспалительных препаратов (НПВП) является циклооксигеназа 2 (ЦОГ2), тем не менее НПВП существенно различаются по фармакологическим свойствам.</p><p>Цель исследования – с помощью хемореактомного анализа установить спектр фармакологического действия декскетопрофена, кетопрофена и диклофенака.</p><sec><title>Материал и методы</title><p>Материал и методы. В процессе хемоинформационного анализа определяли список наиболее близких к декскетопрофену химических структур. Для каждой молекулы из баз данных извлекали результаты экспериментального измерения биологических свойств этой молекулы и проводили хемореактомный анализ. Сравнительный хемореактомный анализ молекулы декскетопрофена и контрольных молекул (кетопрофен, диклофенак) позволил оценить биологические активности исследуемой молекулы.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Установлено, что декскетопрофен в отличие от молекул сравнения может накапливаться преимущественно в мышцах, жировой ткани и надпочечниках. Противовоспалительное и анальгетическое действие декскетопрофена может осуществляться посредством модулирования не только метаболизма простагландинов, но и лейкотриенов и энкефалинов, а также ингибирования металлопротеиназ и глутаматных рецепторов. Кроме того, анализ показал существенное различие профилей взаимодействия декскетопрофена, кетопрофена и диклофенака с ферментами цитохрома Р450. Декскетопрофен может повышать эффективность антиаритмических и антиадренергических средств, тогда как кетопрофен и диклофенак способны негативно влиять на метаболизм омега-3 полиненасыщенных жирных кислот и витамина D.</p></sec><sec><title>Заключение</title><p>Заключение. Хемореактомный анализ позволил выявить, помимо основного действия, перспективные вазодилаторные, антиагрегантные, противодиабетические и противоопухолевые эффекты декскетопрофена. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>нестероидные противовоспалительные препараты</kwd><kwd>декскетопрофен</kwd><kwd>кетопрофен</kwd><kwd>диклофенак</kwd><kwd>системы искусственного интеллекта</kwd></kwd-group><kwd-group xml:lang="en"><kwd>nonsteroidal anti-inflammatory drugs</kwd><kwd>dexketoprofen</kwd><kwd>ketoprofen</kwd><kwd>diclofenac</kwd><kwd>artificial intelligence systems</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Халикова ЕЮ. Декскетопрофена трометамол в амбулаторном обезболивании. Consilium Medicum. Хирургия. 2011;(1):5-10. [Khalikova EYu. Dexketoprofen trometamol in outpatient anesthesia. Consilium Medicum. Khirurgiya. 2011;(1):5-10. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Халикова ЕЮ. Декскетопрофена трометамол в амбулаторном обезболивании. Consilium Medicum. Хирургия. 2011;(1):5-10. [Khalikova EYu. Dexketoprofen trometamol in outpatient anesthesia. Consilium Medicum. Khirurgiya. 2011;(1):5-10. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Moore RA, Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol. 2008 Oct 31;8:11. doi: 10.1186/1472-6904-8-11.</mixed-citation><mixed-citation xml:lang="en">Moore RA, Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol. 2008 Oct 31;8:11. doi: 10.1186/1472-6904-8-11.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wakimoto N, Wolf I, Yin D, et al. Nonsteroidal Anti-inflammatory Drugs Suppress Glioma via 15-Hydroxyprostaglandin Dehydrogenase. Cancer Res. 2008 Sep 1;68(17): 6978-86. doi: 10.1158/0008-5472.CAN-07-5675.</mixed-citation><mixed-citation xml:lang="en">Wakimoto N, Wolf I, Yin D, et al. Nonsteroidal Anti-inflammatory Drugs Suppress Glioma via 15-Hydroxyprostaglandin Dehydrogenase. Cancer Res. 2008 Sep 1;68(17): 6978-86. doi: 10.1158/0008-5472.CAN-07-5675.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006 Oct 4;296(13): 1653-6. Epub 2006 Sep 12.</mixed-citation><mixed-citation xml:lang="en">Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006 Oct 4;296(13): 1653-6. Epub 2006 Sep 12.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Torshin IYu. Bioinformatics in the postgenomic era: physiology and medicine. New York: NovaBiomedicalBooks; 2007.</mixed-citation><mixed-citation xml:lang="en">Torshin IYu. Bioinformatics in the postgenomic era: physiology and medicine. New York: NovaBiomedicalBooks; 2007.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Журавлёв ЮИ, Рудаков КВ, Торшин ИЮ. Алгебраические критерии локальной разрешимости и регулярности как инструмент исследования морфологии аминокислотных последовательностей. Труды МФТИ. 2011;3(4):67-76. [Zhuravlev YuI, Rudakov KV, Torshin IYu. Algebraic criteria of local solvability and regularity as a tool for studying the morphology of amino acid sequences. Trudy MFTI. 2011;3(4):67-76. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Журавлёв ЮИ, Рудаков КВ, Торшин ИЮ. Алгебраические критерии локальной разрешимости и регулярности как инструмент исследования морфологии аминокислотных последовательностей. Труды МФТИ. 2011;3(4):67-76. [Zhuravlev YuI, Rudakov KV, Torshin IYu. Algebraic criteria of local solvability and regularity as a tool for studying the morphology of amino acid sequences. Trudy MFTI. 2011;3(4):67-76. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Рудаков КВ, Торшин ИЮ. Об отборе информативных значений признаков на базе критериев разрешимости в задаче распознавания вторичной структуры белка. ДАН. 2011;(1):1-5. [Rudakov KV, Torshin IYu. About selection of informative values of signs on the basis of solvability criteria in the problem of recognition of secondary structure of protein. DAN. 2011;(1):1-5. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Рудаков КВ, Торшин ИЮ. Об отборе информативных значений признаков на базе критериев разрешимости в задаче распознавания вторичной структуры белка. ДАН. 2011;(1):1-5. [Rudakov KV, Torshin IYu. About selection of informative values of signs on the basis of solvability criteria in the problem of recognition of secondary structure of protein. DAN. 2011;(1):1-5. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Журавлев ЮИ. Об алгебраическом подходе к решению задач распознавания или классификации. Проблемы кибернетики. 1978; (3):5-68. [Zhuravlev YuI. On an algebraic approach to solving recognition or classification problems. Problemy kibernetiki. 1978;(3):5-68. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Журавлев ЮИ. Об алгебраическом подходе к решению задач распознавания или классификации. Проблемы кибернетики. 1978; (3):5-68. [Zhuravlev YuI. On an algebraic approach to solving recognition or classification problems. Problemy kibernetiki. 1978;(3):5-68. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Торшин ИЮ, Громова ОА. Экспертный анализ данных в молекулярной фармакологии. Москва: МЦНМО; 2012. 768 с. [Torshin IYu, Gromova OA. Ekspertnyi analiz dannykh v molekulyarnoi farmakologii [Expert data analysis in molecular pharmacology]. Moscow: MTsNMO; 2012. 768 p.]</mixed-citation><mixed-citation xml:lang="en">Торшин ИЮ, Громова ОА. Экспертный анализ данных в молекулярной фармакологии. Москва: МЦНМО; 2012. 768 с. [Torshin IYu, Gromova OA. Ekspertnyi analiz dannykh v molekulyarnoi farmakologii [Expert data analysis in molecular pharmacology]. Moscow: MTsNMO; 2012. 768 p.]</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng T, Pan Y, Hao M, Wang Y, Bryant SH. PubChem applications in drug discovery: a bibliometric analysis. Drug Discov Today. 2014 Nov;19(11):1751-1756.</mixed-citation><mixed-citation xml:lang="en">Cheng T, Pan Y, Hao M, Wang Y, Bryant SH. PubChem applications in drug discovery: a bibliometric analysis. Drug Discov Today. 2014 Nov;19(11):1751-1756.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Wishart DS, Tzur D, Knox C, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6.</mixed-citation><mixed-citation xml:lang="en">Wishart DS, Tzur D, Knox C, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Si H, Liu D. Phytochemical genistein in the regulation of vascular function: new insights. Curr Med Chem. 2007;14(24):2581-9.</mixed-citation><mixed-citation xml:lang="en">Si H, Liu D. Phytochemical genistein in the regulation of vascular function: new insights. Curr Med Chem. 2007;14(24):2581-9.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Onaka Y, Shintani N, Nakazawa T, et al. Prostaglandin D2 signaling mediated by the CRTH2 receptor is involved in MK-801-induced cognitive dysfunction. Behav Brain Res. 2016 Nov 1;314:77-86. doi: 10.1016/j.bbr.2016. 07.050. Epub 2016 Jul 29.</mixed-citation><mixed-citation xml:lang="en">Onaka Y, Shintani N, Nakazawa T, et al. Prostaglandin D2 signaling mediated by the CRTH2 receptor is involved in MK-801-induced cognitive dysfunction. Behav Brain Res. 2016 Nov 1;314:77-86. doi: 10.1016/j.bbr.2016. 07.050. Epub 2016 Jul 29.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Joo HW, Kang YR, Kwack MH, Sung YK. 15-deoxy prostaglandin J2, the nonenzymatic metabolite of prostaglandin D2, induces apoptosis in keratinocytes of human hair follicles: a possible explanation for prostaglandin D2-mediated inhibition of hair growth. Naunyn Schmiedebergs Arch Pharmacol. 2016 Jul;389(7): 809-13. doi: 10.1007/s00210-016-1257-z. Epub 2016 May 17.</mixed-citation><mixed-citation xml:lang="en">Joo HW, Kang YR, Kwack MH, Sung YK. 15-deoxy prostaglandin J2, the nonenzymatic metabolite of prostaglandin D2, induces apoptosis in keratinocytes of human hair follicles: a possible explanation for prostaglandin D2-mediated inhibition of hair growth. Naunyn Schmiedebergs Arch Pharmacol. 2016 Jul;389(7): 809-13. doi: 10.1007/s00210-016-1257-z. Epub 2016 May 17.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Meyer HC. Alopecia associated with ibuprofen. JAMA. 1979 Jul 13;242(2):142.</mixed-citation><mixed-citation xml:lang="en">Meyer HC. Alopecia associated with ibuprofen. JAMA. 1979 Jul 13;242(2):142.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tang Y, Fung E, Xu A, Lan HY. C-reactive protein and ageing. Clin Exp Pharmacol Physiol. 2017 Dec;44 Suppl 1:9-14. doi: 10.1111/1440-1681.12758. Epub 2017 Aug 24.</mixed-citation><mixed-citation xml:lang="en">Tang Y, Fung E, Xu A, Lan HY. C-reactive protein and ageing. Clin Exp Pharmacol Physiol. 2017 Dec;44 Suppl 1:9-14. doi: 10.1111/1440-1681.12758. Epub 2017 Aug 24.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Benson C, Mifflin K, Kerr B, et al. Biogenic Amines and the Amino Acids GABA and Glutamate: Relationships with Pain and Depression. Mod Trends Pharmacopsychiatry. 2015;30:67-79. doi: 10.1159/000435933. Epub 2015 Sep 18.</mixed-citation><mixed-citation xml:lang="en">Benson C, Mifflin K, Kerr B, et al. Biogenic Amines and the Amino Acids GABA and Glutamate: Relationships with Pain and Depression. Mod Trends Pharmacopsychiatry. 2015;30:67-79. doi: 10.1159/000435933. Epub 2015 Sep 18.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
